What one share of Eledon Pharmaceuticals holds
Eledon is a clinical stage biotechnology company using our immunology expertise in targeting the CD40 Ligand (“CD40L”) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (“ALS”).
Eledon Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.94 |
|---|---|
| Cash and investments | $0.08 |
| Debt | $0.00 |
| Book value | $0.41 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | $0.00 | −$559.58 | $0.46 | −$539.81 | — | −$2,306 |
| 2013 | $0.00 | −$684.42 | $1.00 | −$670.57 | — | −$2,017 |
| 2014 | $0.00 | −$64.82 | $0.07 | −$58.84 | — | — |
| 2015 | $0.00 | −$36.09 | $0.45 | −$33.46 | — | $2.22 |
| 2018 | — | −$28.11 | — | — | — | $27.69 |
| 2019 | — | −$24.42 | — | — | — | $13.14 |
| 2020 | — | −$15.72 | — | — | — | — |
| 2021 | — | −$2.33 | — | — | — | $11.46 |
| 2022 | — | −$6.16 | — | — | — | $1.73 |
| 2023 | — | −$4.73 | — | — | — | −$2.00 |
| 2024 | — | −$0.66 | — | — | — | $1.04 |
| 2025 | — | −$0.52 | — | — | — | $1.07 |
Common questions about Eledon Pharmaceuticals
How much does one share of Eledon Pharmaceuticals earn?
Over the last 12 months, Eledon Pharmaceuticals lost $0.94 for each share.
Does Eledon Pharmaceuticals pay a dividend?
Eledon Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Eledon Pharmaceuticals’s book value per share?
Eledon Pharmaceuticals’s book value is $0.41 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Eledon Pharmaceuticals have?
Each share of Eledon Pharmaceuticals has $0.08 of cash and investments and $0.00 of debt, as of June 30, 2026.
Has Eledon Pharmaceuticals bought back shares?
Eledon Pharmaceuticals’s share count rose about 472829% from 2012 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.